190 related articles for article (PubMed ID: 24443001)
1. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.
Vital EM; Dass S; Buch MH; Rawstron AC; Emery P
Ann Rheum Dis; 2015 Jun; 74(6):1195-201. PubMed ID: 24443001
[TBL] [Abstract][Full Text] [Related]
2. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.
Vital EM; Rawstron AC; Dass S; Henshaw K; Madden J; Emery P; McGonagle D
Arthritis Rheum; 2011 Mar; 63(3):603-8. PubMed ID: 21360489
[TBL] [Abstract][Full Text] [Related]
3. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.
Vital EM; Dass S; Rawstron AC; Buch MH; Goëb V; Henshaw K; Ponchel F; Emery P
Arthritis Rheum; 2010 May; 62(5):1273-9. PubMed ID: 20131284
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T
N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).
Emery P; Deodhar A; Rigby WF; Isaacs JD; Combe B; Racewicz AJ; Latinis K; Abud-Mendoza C; Szczepanski LJ; Roschmann RA; Chen A; Armstrong GK; Douglass W; Tyrrell H
Ann Rheum Dis; 2010 Sep; 69(9):1629-35. PubMed ID: 20488885
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.
Wijesinghe H; Galappatthy P; de Silva R; Seneviratne SL; Saravanamuttu U; Udagama P; Hart M; Kelleher P; Senerath U; Fernandopulle R; Weerasekera LP; Wijayaratne LS
BMC Musculoskelet Disord; 2017 Jul; 18(1):310. PubMed ID: 28724365
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
9. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
10. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.
Dass S; Rawstron AC; Vital EM; Henshaw K; McGonagle D; Emery P
Arthritis Rheum; 2008 Oct; 58(10):2993-9. PubMed ID: 18821683
[TBL] [Abstract][Full Text] [Related]
11. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.
Rivellese F; Nerviani A; Giorli G; Warren L; Jaworska E; Bombardieri M; Lewis MJ; Humby F; Pratt AG; Filer A; Gendi N; Cauli A; Choy E; McInnes I; Durez P; Edwards CJ; Buch MH; Gremese E; Taylor PC; Ng N; Cañete JD; Raizada S; McKay ND; Jadon D; Sainaghi PP; Stratton R; Ehrenstein MR; Ho P; Pereira JP; Dasgupta B; Gorman C; Galloway J; Chinoy H; van der Heijde D; Sasieni P; Barton A; Pitzalis C;
Lancet Rheumatol; 2023 Nov; 5(11):e648-e659. PubMed ID: 38251532
[TBL] [Abstract][Full Text] [Related]
12. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F; Durez P; Buch MH; Lewis MJ; Rizvi H; Rivellese F; Nerviani A; Giorli G; Mahto A; Montecucco C; Lauwerys B; Ng N; Ho P; Bombardieri M; Romão VC; Verschueren P; Kelly S; Sainaghi PP; Gendi N; Dasgupta B; Cauli A; Reynolds P; Cañete JD; Moots R; Taylor PC; Edwards CJ; Isaacs J; Sasieni P; Choy E; Pitzalis C;
Lancet; 2021 Jan; 397(10271):305-317. PubMed ID: 33485455
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
van Vollenhoven RF; Wax S; Li Y; Tak PP
Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
15. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
[TBL] [Abstract][Full Text] [Related]
16. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
17. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
Smolen JS; Weinblatt ME; Sheng S; Zhuang Y; Hsu B
Ann Rheum Dis; 2014 Sep; 73(9):1616-25. PubMed ID: 24699939
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.
Taylor PC; Quattrocchi E; Mallett S; Kurrasch R; Petersen J; Chang DJ
Ann Rheum Dis; 2011 Dec; 70(12):2119-25. PubMed ID: 21859685
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.
Mariette X; Rouanet S; Sibilia J; Combe B; Le Loët X; Tebib J; Jourdan R; Dougados M
Ann Rheum Dis; 2014 Aug; 73(8):1508-14. PubMed ID: 23723317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
